- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic lymphocytic leukaemia or small lymphocytic leukaemia
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 902KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 322KB)
Zanubrutinib – March 2023
Zanubrutinib (relapsed/refractory CLL/SLL): Capsule 80 mg; Brukinsa®
Last updated
30 June 2023